SRR1337412
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1341702 | GTEX | — | 0.961 |
| 2 | SRR1383059 | GTEX | — | 0.955 |
| 3 | BS_044XZ8ST | pilocytic astrocytoma | — | 0.945 |
| 4 | SRR1359171 | GTEX | — | 0.945 |
| 5 | SRR1381757 | GTEX | — | 0.935 |
| 6 | BS_4BWB0FA0 | low-grade glioma | — | 0.933 |
| 7 | SRR1352954 | GTEX | — | 0.928 |
| 8 | BS_3XY76V8T | Ganglioglioma | — | 0.926 |
| 9 | SRR1444622 | GTEX | — | 0.923 |
| 10 | SRR1338923 | GTEX | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.513 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.450 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.417 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.408 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.388 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.376 | Idelalisib | — uncovered |
| APOPTOSIS | 0.336 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.332 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.326 | Inavolisib | — uncovered |
| COAGULATION | 0.325 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.319 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.299 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.287 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.285 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.278 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.273 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.272 | Inavolisib | — uncovered |
| HYPOXIA | 0.258 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.253 | Remibrutinib | — uncovered |